Global action plan
Preventing and managing the emergence of HIV drug resistance is a key component of a comprehensive and effective HIV response. This should be integrated into broader efforts to ensure sustainability and greatest impact. It is essential that actions to monitor, prevent and respond to HIV drug resistance are implemented at the clinical, programme and policy levels to address the many drivers of HIV drug resistance.
The “Global action plan on HIV drug resistance” provides a comprehensive framework for action by countries, WHO and other stakeholders. It describes a package of interventions and resources to guide the response to HIV drug resistance.
The Global Action Plan on HIV drug resistance 2017–2021 provided a comprehensive framework for global and country action and outlined a package of...
The rise in antimicrobial resistance is a growing global health concern that requires collective and coordinated action. Minimizing the emergence and transmission...
Strategy
To minimize the emergence and spread of HIV drug resistance, WHO recommends that antiretroviral therapy and pre-exposure prophylaxis programmes be accompanied by the monitoring and surveillance of HIV drug resistance.
In 2004, WHO in collaboration with the HIV Drug Resistance Network – a global organization that advises WHO on HIV drug resistance – developed a strategy for the assessment and prevention of HIV drug resistance. This strategy is regularly updated to take into account the status of the ongoing scale-up of antiretroviral therapy and pre-exposure prophylaxis programmes.
HIV drug resistance surveillance guidance
To date, levels of HIV drug resistance (HIVDR) in countries scaling up ART remain manageable; however, they are slowly increasing. For example, in East...
The document summarizes a comprehensive package of HIV drug resistance surveys that should be implemented in all countries scaling-up and maintaining populations...